Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYXH) is a medical technology company that develops and commercializes neuromodulation-based therapies for obstructive sleep apnea (OSA), centered on its Genio hypoglossal neurostimulation system. The Nyxoah news feed on Stock Titan brings together company-issued announcements, regulatory disclosures and market updates that reflect how the business is progressing in its target markets.
Investors following Nyxoah’s news can track updates on U.S. and European commercialization of the Genio system, including surgeon training, account activations and the completion of commercial implants. Company press releases describe milestones such as the commercial launch of Genio in new countries, early U.S. implant activity after FDA approval, and developments in reimbursement coverage with public and private payers.
Nyxoah also regularly reports on its financial position and capital markets activity. News items include quarterly financial and operating results, preliminary revenue updates, private placements, registered direct offerings and convertible bond financings, as well as information on voting rights, share capital and transparency notifications regarding significant shareholdings. These disclosures provide context on how the company funds its commercialization and research plans.
In addition, the news stream features regulatory and legal developments, such as FDA approval of the Genio system for a defined subset of adult OSA patients, CE mark expansions, and intellectual property litigation updates referenced in company filings. By reviewing the NYXH news page, readers can see how Nyxoah communicates progress on clinical, regulatory, commercial and financing fronts over time.
Nyxoah (NASDAQ:NYXH) announced the publication of its DREAM pivotal study data in the Journal of Clinical Sleep Medicine, showcasing comprehensive 12-month safety and efficacy results for its Genio® system in treating Obstructive Sleep Apnea (OSA).
The study demonstrated strong results with 63.5% AHI responder rate and 71.3% ODI responder rate. Patient engagement was remarkable, with 84.3% of participants using the device more than 4 hours in over 70% of nights, and 90% of patients expressing satisfaction. The device showed a 66.6% median reduction in supine AHI at 12 months.
Safety results aligned with other neuromodulation therapies, showing 11 serious adverse events in ten subjects (8.7% SAE rate), with only three being device-related. Quality-of-life outcomes improved significantly, with a 2.3-point increase in FOSQ assessment and 3.4-point reduction in Epworth Sleepiness Score.
Nyxoah (NASDAQ/Euronext: NYXH) has disclosed its updated share capital and voting rights information as of June 27, 2025. The company's share capital stands at EUR 6,431,121.38 with a total of 37,435,640 ordinary shares, each carrying one voting right. Additionally, there are 2,822,816 subscription rights not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.
Nyxoah SA (NYXH), a medical technology company focused on developing innovative treatments for Obstructive Sleep Apnea (OSA), has announced its participation in the upcoming Jefferies Global Healthcare Conference in New York from June 3-5, 2025. CEO Olivier Taelman will deliver a corporate presentation on June 4, 2025, at 4:55pm ET. The presentation will be accessible via webcast on Nyxoah's Investor Relations website's Events section. The company will also be available for one-on-one meetings with institutional investors during the conference.
Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its share capital and voting rights structure as of May 23, 2025. The company's share capital stands at EUR 6,430,026.16. The total number of securities carrying voting rights is 37,429,265 ordinary shares, with an equal number of voting rights. Additionally, there are 2,854,068 subscription rights to securities not yet issued, excluding 478,057 subscription rights that were issued but not yet granted.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has received a transparency notification from FMR LLC regarding changes in shareholding. FMR LLC and its controlled undertakings now hold 1,111,240 voting rights (2.97% of total voting rights) as of April 29, 2025, consisting of 987,776 voting rights linked to securities and 123,464 equivalent financial instruments. This represents a downward crossing below the 3% threshold.
The voting rights are distributed among Fidelity Management & Research Company LLC (2.07%), FIAM LLC (0.00%), and FMR Investment Management UK Limited (0.57%). The notification includes a stock loan as an equivalent financial instrument representing 0.33% of voting rights.
Nyxoah (Nasdaq/Euronext: NYXH), a company focused on developing innovative neuromodulation treatments for Obstructive Sleep Apnea (OSA), has scheduled its Q1 2025 financial results release for May 14, 2025. The company will host a conference call with management on the same day at 2:00pm CET / 8:00am ET.
Investors and analysts can access the earnings call through the company's Investor Relations webpage or via webcast link. Those planning to ask questions during the call should register at least 10 minutes before the start time using a separate registration link. A replay of the webcast will be available shortly after the call concludes.